Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission

被引：18
|
作者：
Chou, W-C [1 ,2 ]
Peng, K-Y [3 ,4 ]
Lei, W-C [2 ]
Ko, B-S [2 ]
Tsay, W. [2 ]
Kuo, C-H [3 ,5 ]
Tien, H-F [2 ]
机构：
[1] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Lab Med, Taipei 10764, Taiwan
[2] Natl Taiwan Univ, Natl Taiwan Univ Hosp, Dept Internal Med, Div Hematol, Taipei 10764, Taiwan
[3] Natl Taiwan Univ, Ctr Genom Med, Metabol Core Lab, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Coll Publ Hlth, Inst Environm Hlth, Taipei 10764, Taiwan
[5] Natl Taiwan Univ, Coll Med, Dept Pharm, Taipei 10764, Taiwan
来源：
LEUKEMIA | 2012年 / 26卷 / 03期
关键词：
INTERNAL TANDEM DUPLICATION; IDH2; MUTATIONS; BEARING; GLIOMAS;
D O I：
10.1038/leu.2011.215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：527 / 529
页数：3
相关论文
共 50 条
  • [1] Persistence of mutant isocitrate dehydrogenase in patients with acute myeloid leukemia in remission
    W-C Chou
    K-Y Peng
    W-C Lei
    B-S Ko
    W Tsay
    C-H Kuo
    H-F Tien
    Leukemia, 2012, 26 : 527 - 529
  • [2] A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia
    Verma, Amit
    Steidl, Ulrich
    NATURE MEDICINE, 2015, 21 (02) : 113 - 114
  • [3] A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia
    Amit Verma
    Ulrich Steidl
    Nature Medicine, 2015, 21 : 113 - 114
  • [4] Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
    Liu, Xiaoyan
    Gong, Yuping
    BIOMARKER RESEARCH, 2019, 7 (01)
  • [5] Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
    Xiaoyan Liu
    Yuping Gong
    Biomarker Research, 7
  • [6] Immunosuppression in Isocitrate Dehydrogenase Mutated Acute Myeloid Leukemia
    Tai, Jesse W.
    Li, Guan
    Tanaka, Kailee
    Gopakumar, Jayakrishnan
    Zhou, Crystal
    Linde, Miles Hamilton
    Villar-Prados, Alejandro
    Rangavajhula, Athreya S.
    Trotman-Grant, Aaron C.
    Landberg, Niklas
    Fan, Amy C.
    Mannis, Gabriel
    Zhang, Tian Y.
    BLOOD, 2023, 142
  • [7] Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
    DiNardo, Courtney D.
    Stein, Anthony S.
    Stein, Eytan M.
    Fathi, Amir T.
    Frankfurt, Olga
    Schuh, Andre C.
    Dohner, Hartmut
    Martinelli, Giovanni
    Patel, Prapti A.
    Raffoux, Emmanuel
    Tan, Peter
    Zeidan, Amer M.
    de Botton, Stephane
    Kantarjian, Hagop M.
    Stone, Richard M.
    Frattini, Mark G.
    Lersch, Frederik
    Gong, Jing
    Gianolio, Diego A.
    Zhang, Vickie
    Franovic, Aleksandra
    Fan, Bin
    Goldwasser, Meredith
    Daigle, Scott
    Choe, Sung
    Wu, Bin
    Winkler, Thomas
    Vyas, Paresh
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (01) : 57 - +
  • [8] Isocitrate Dehydrogenase 1 Mutation and Ivosidenib in Patients With Acute Myeloid Leukemia: A Comprehensive Review
    Tangella, Adarsh Vardhan
    Gajre, Ashwin
    Kantheti, Vivek Varma
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (09)
  • [9] Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML)
    Cortes, Jorge
    Jonas, Brian A.
    Schiller, Gary
    Mims, Alice
    Roboz, Gail J.
    Wei, Andrew H.
    Montesinos, Pau
    Ferrell, P. Brent
    Yee, Karen W. L.
    Fenaux, Pierre
    Schwarer, Anthony
    Watts, Justin M.
    LEUKEMIA & LYMPHOMA, 2024, 65 (08) : 1145 - 1152
  • [10] Persistence of Exosomes in Patients with Acute Myeloid Leukemia in Complete Remission Suppresses Hematopoiesis
    Namburi, Swathi
    Broxmeyer, Hal E.
    Whiteside, Theresa L.
    Boyiadzis, Michael
    BLOOD, 2018, 132
12345